Chemogene therapy: Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a marine osteosarcoma model

Cancer Gene Therapy

Volumn 4, Issue 6, 1997, Pages 359-365

  Cheon, Jun ^a   Ko, Song Chu ^a   Gardner, Thomas A ^a,c   Shirakawa, Toshiro ^a   Gotoh, Akinobu ^b   Kao, Chinghai ^a   Chung, Leland W K ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b KOBE UNIVERSITY   (Japan)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Animal model; Chemogene therapy; Gene therapy; Methotrexate; Osteocalcin promoter; Osteosarcoma; Thymidine kinase

Indexed keywords

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

ACICLOVIR; HYBRID PROTEIN; METHOTREXATE; OSTEOCALCIN; THYMIDINE KINASE;

ADENOVIRUS; ANIMAL; ARTICLE; BIOSYNTHESIS; BONE TUMOR; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECT; GENE THERAPY; GENETICS; HUMAN; METHODOLOGY; MOUSE; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; OSTEOSARCOMA; PROMOTER REGION; RAT; SURVIVAL; XENOGRAFT;

ACYCLOVIR; ADENOVIRIDAE; ANIMALS; BONE NEOPLASMS; CELL LINE; CELL SURVIVAL; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; METHOTREXATE; MICE; MICE, NUDE; OSTEOCALCIN; OSTEOSARCOMA; PROMOTER REGIONS (GENETICS); RATS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; THYMIDINE KINASE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031267107     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Vander-Griend RA. Osteosarcoma and its variants. Orthop Clin North Am. 1996;27:575-581.
2. Damron TA, Pritchard DJ. Current combined treatment of high-grade osteosarcomas. Oncology. 1995;9:327-350.
3. Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP. Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long term survival. Cancer. 1995;75:1084-1093.
4. O'Reilly R. National comprehensive cancer network pediatric osteosarcoma practice guidelines. Oncology. 1996;10: 1799-1806.
5. Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, Holmes EC, Eilber FR, Eckardt JJ. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol. 1994;12:1849-1858.
6. Malawer MM, Link MP, Donaldson SS. Sarcomas of bone. In: DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia: J.B. Lippincott Company; 1993:1509-1566.
7. Skotzko M, Wu L, Anderson WF, Gordon EM, Hall FL. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res. 1995;55:5493-5498.
8. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995;18:93-99.
9. Ko SC, Cheon J, Kao C, et al. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res. 1996;56:4614-4619.
10. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 1996;2:985-991.
11. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1997;89:21-39.
12. Velez-Yanguas MC, Warrier RP. The evolution of chemotherapeutic agents for the treatment of pediatric musculoskeletal malignancies. Orthop Clin North Am. 1996;27:545-549.
13. Wada T, Isu K, Takeda N, Usui M, Ishii S, Yamawaki S. A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Oncology. 1996; 53:221-227.
14. Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities: the Istituto Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer. 1990;65:2539-2553.
15. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Clin Orthop. 1991;270:4-7.
16. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med. 1996;335:1041-1048.
17. Krakoff IH. Systemic treatment of cancer. CA. 1996;46: 134-141.
18. Ives DH, Furham JP, Tucker VS. Rapid determination of nucleotide kinase and nucleotidase activities with tritiumlabeled substances. Anal Biochem. 1969;28:192-205.
19. Tosi P, Calabresi P, Goulette FA, et al. Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. Cancer Res. 1992;52: 4069-4073.